期刊文献+

华法林与心血管系统钙化 被引量:1

下载PDF
导出
摘要 心房颤动是临床最常见的心律失常,我国和全世界范围内现有心房颤动患者已分别超过800万和3300万,伴随全球人口老龄化的进程,心房颤动患者还会进一步增多。心房颤动最常见、最严重的并发症是因心房内血栓脱落引发的严重栓塞事件:心房颤动患者发生脑卒中的风险是正常人的5~6倍,占所有脑卒中病例的15%~25%,是我国人群最主要的致残原因;而且心房颤动伴发的血栓栓塞事件还有复发率高的特点,使之成为严重危害人群健康与生命的重大慢病[1]。因此,抗凝防栓是心房颤动治疗策略中重要组成部分。
出处 《心肺血管病杂志》 2020年第7期868-871,共4页 Journal of Cardiovascular and Pulmonary Diseases
基金 国家自然科学基金资助项目(8177020247)。
  • 相关文献

参考文献2

二级参考文献40

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 3Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 4Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 5Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 6Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 7Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 8Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.
  • 9Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11 : 493 -496.
  • 10Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med, 2011,155:653-659.

共引文献604

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部